Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
In the phase I trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, in the phase II trial, the safety and efficacy of chidamide+VRD will be compared with that of VRD regimen.
Multiple Myeloma
DRUG: Chidamide+VRD|DRUG: VRD
complete remission rate, complete remission rate after treated by the corresponding regimen, at the time point 1 month after the last cycle|incidence and severity of adverse events, any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure, from the date of the start of treatment to 36 months after last patient's enrollment
progression free survival, from date of inclusion to date of progression, relapse, or death from any cause, from the day of treatment to the date of first documented progression，up to 36 months after the last patient's enrollment;|overall survival, from the date of inclusion to date of death, irrespective of cause, from the day of treatment to the date of first documented progression，up to 36 months after the last patient's enrollment
In the phase I trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, which will be determined by efficacy and safety profiles of the patients; afterward, the optimal dosage of chidamide will be combined with VRD regimen, patients will be randomly assigned to chidamide+VRD group or VRD group, and their efficacy and safety will be compared.